Seen in the press: Nemera’s CEO interview in ‘The Pharma Post’ special COVID-19 editionMay 5, 2020
“This is a significant learning opportunity for us as a global community.”
Marc Hämel, our CEO shares his thoughts on leading Nemera during the coronavirus pandemic in Pharma Post’s Special issue ‘Pharma Post Covid-19’.
“When the COVID-19 outbreak began in China, we were all hearing about it but the scale of the spread of the virus was still unknown. We had created and activated a business continuity plan prior to the pandemic. As the situation started escalating we promptly implemented the initial safety measures recommended by the health authorities – travel restrictions, social distancing, basic sanitary practices in our premises, visual aids to wash hands correctly and installing hand sanitizer dispensers at the entry doors of all our buildings.
As the outbreak continued, governments and health authorities implemented radical safety measures and we complied. You may know that Nemera has 4 manufacturing sites: La Verpillère and Le Tréport in France, Neuenburg in Germany and Buffalo Grove in the United States. The local health authorities’ recommendations are not the same everywhere so our manufacturing sites are complying with the local authorities’ recommendations but in some instances we took early measures. Our BCP (Business Continuity Plan) Pandemic committee is instrumental in ensuring governance and management of the crisis on a regular basis.
Our employees who can work from home are doing so, telecommunicating and staying connected. We are monitoring the situation closely and are in contact with the health authorities to make sure we are doing everything we can to protect our employees.
Our ongoing strong and regular interactions with customers and suppliers help us to effectively manage stock levels, identify supply risks and manage them pro-actively. We also keep our business partners updated.
None of us imagined we would be living through times like these. Every phase of this pandemic is unprecedented and we are inundated with guidelines to keep ourselves and our loved ones safe. We were not completely prepared for such a crisis but we mobilized quickly and acted swiftly to keep the situation under control. I’m really proud of the agility with which people at Nemera have come together, adapted new ways of working and are extending help when needed to their colleagues in the manufacturing sites.”
To read more :
The full article:
The full issue of the magazine:
Nemera is a world leader in the design, development, and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera offers a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. Nemera’s vision is to be the most patient-centric drug delivery device company. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health
Nemera’s newly branded Insight Innovation Center, with offices in North America and Europe, provides consultative services to support your overall device strategy. Providing user research, Human Factors, User Experience design, and Design for manufacturing, the Insight Innovation Center can help customers navigate their device strategy for both novel and platform solutions. Users are at the center of everything that we do in our effort to always put patients first.